Kornimate/medical-research-clean huggingface dataset:
ten-year follow-up of laser in situ keratomileusis in patients 8 to 15 years old

Conditions: Anisometropia

Summary: the purpose of this study is to determine the safety, efficacy, predictability, and stability of laser in situ keratomileusis (lasik) to correct high anisometropia in patients 8 to 15 years old in whom conventional treatments have failed.

nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 d), were included in this study. minimum follow-up was 10 years. all patients were treated with the chiron technolas 217 excimer laser.

Eligibility criteria:
inclusion criteria: * high anisometropia (\>3.50 d) * patients 8 to 15 years old * conventional treatments have failed exclusion criteria: * diabetes * autoimmune diseases * topographic abnormalities

Keywords: lasik safety efficacy stability high anisometropia patients 8 to 15 years old conventional treatments have failed
trial of myopia prevention using +3d lenses

Conditions: Myopia

Summary: the purpose of this study is to assess whether a short-term imposed myopic defocus is effective in preventing the development and progression of juvenile-onset myopia in chinese children.

1. to determine if +3d lenses wearing for half an hour everyday prevents the development and progression of myopia in school children. 2. to identify ocular parameters and risk factors at baseline associated with development and progression of myopia.

Eligibility criteria:
inclusion criteria: * all children in the selected class are enrolled exclusion criteria: * hyperopia \> +2.0 d * high myopia \> -6.0 d * astigmatism\> 1.5 d * anisometropia \> 1.5 d * strabismus and amblyopia * any ocular, systemic, or neurodevelopmental conditions that could influence refractive development * chronic medication use that might affect myopia progression or visual acuity * already receiving other treatment for progressing myopia
the protect (prep optimization through telehealth care and treatment) trial

Conditions: HIV Prevention

Summary: the expansion of hiv pre-exposure prophylaxis (prep) care has been endorsed as a key strategy for reducing new hiv infections, however, prep trials among people who inject drugs (pwid) are rare and uptake of prep has been minimal, most notably in rural areas. structural barriers to healthcare access, lack of providers, and inadequate infrastructure to deliver prep are challenges in many rural areas. in addition, pwid often have social determinant barriers to prep care. this study will integrate telehealth prep care within syringe services programs (ssps), a venue already routinely accessed by pwid, to reduce structural barriers to evidence-based hiv prevention through co-located comprehensive prep services, and test this against a standard of care approach in a pilot randomized clinical trial. the primary objective is to examine preliminary efficacy and effect sizes of novel integrated telehealth care versus standard education and active referral on the primary outcome of prep initiation in hiv-negative participants who inject drugs.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * report at least one occasion of injection drug use in the past month * report an indication for prep in the past six months consistent with cdc guidelines for prep care * be a documented client of the county ssp at the time of study entry * express willingness to participate in a multi-session intervention and follow-up exclusion criteria: * hiv-positive status * current prep care.
insulin producing stem cell transplantation clinical trial in type 1 diabetes

Conditions: Stem Cells; Type 1 Diabetes

Summary: type 1 diabetes is a chronic autoimmune disease. it results from autoimmune destruction of pancreatic beta cells leading to absolute insulin insufficiency. the establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. in the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

differentiation of stem cells from various sources to form insulin-producing cells (ipcs) provides a new and promising strategy to reconstitute pancreatic endocrine function. studies recently developed a multistep differentiation technique for the differentiation of human embryonic stem cells to form pancreatic progenitors. at the end of in vitro differentiation approximately 5% of cells became insulin positive. mesenchymal stem cells (mscs) can be derived from various sources. mscs are undifferentiated cells with multilinear potential, known for their immunomodulatory and regenerative properties . the bone marrow, adipose tissue, umbilical cord, liver cells, and endometrium are among several tissues that are rich in mscs. of these, the bone marrow and adipose tissues offer distinct advantages in view of their availability and abundance and the extent of their documentation. in this study the investigators aim to obtain autologous differentiated insulin producing mesenchymal stem cells (derived from adipose tissue) and their introduction in human subjects with type 1 diabetes. the current study will assess of the ability of the transplanted cells to produce insulin both in vitro and in vivo. post- transplant glycemic control will be assessed with possible amelioration of the standard treatment of type 1 diabetes.

Eligibility criteria:
inclusion criteria: * type 1 diabetes exclusion criteria: * patients with other autoimmune diseases * patients with micro or macro vascular complications * patients with other chronic diseases
a maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer

Conditions: Ovarian Neoplasms; Platinum Sensitive Ovarian Cancer

Summary: this is a phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gbrcamut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. niraparib is an orally active parp inhibitor. niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. health-related quality of life will be measured by the functional assessment of cancer therapy - ovarian symptom index (fosi), european quality of life scale, 5-dimensions (eq-5d), and a neuropathy questionnaire. safety and tolerability will be assessed by clinical review of adverse events (aes), physical examinations, electrocardiograms (ecgs), and safety laboratory values. the primary objective of this study is to evaluate efficacy of niraparib as maintenance therapy in patients who have platinum sensitive ovarian cancer as assessed by the prolongation of progression free survival (pfs).


Eligibility criteria:
inclusion criteria: * 18 years of age or older, female, any race * histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer * high grade (or grade 3) serous histology or known to have gbrcamut * has received at least 2 previous courses of platinum-containing therapy, and has disease that was considered platinum sensitive following the penultimate (next to last) platinum course (more than 6 month period between penultimate platinum regimen and progression of disease) * has responded to last the platinum regimen, remains in response and is enrolled on study within 8 weeks of completion of the last platinum regimen * ecog 0-1 * adequate bone marrow, kidney and liver function exclusion criteria: * known hypersensitivity to the components of niraparib * invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated) * symptomatic uncontrolled brain metastasis * is pregnant or breast feeding * immunocompromised patients * known active hepatic disease * prior treatment with a known parp inhibitor

Keywords: ovarian cancer platinum sensitive gbrcamut brca high-grade serous histology parp inhibitor
good night project: behavioural sleep interventions for children with adhd: a randomised controlled trial

Conditions: Attention Deficit Hyperactivity Disorders; Neurodevelopmental Disorders; Attention Deficit Disorder With Hyperactivity

Summary: the study aims to implement and evaluate an rct of behavioural sleep interventions for children aged 5-12 years with adhd, and their primary caregivers, (women) in saudi arabia to address the following questions: 1. to what extent can a behavioural intervention improve sleep difficulties and increase sleep duration in children with adhd? 2. to what extent do intervention-induced changes in sleep for children or primary caregivers (women) account for any changes in adhd symptoms?


Eligibility criteria:
inclusion criteria: * the participants will be primary caregivers (women) of children aged 5-12 years who have been diagnosed with adhd by a psychiatrist, using the criteria taken from diagnostic and statistical manual of mental disorders-5 in saudi arabia. * children with comorbidities will be also included. * sleep difficulties are defined as a total score of over 41 in the children's sleep habits questionnaire (cshq). exclusion criteria: children will be excluded from the study if they meet any of the following criteria: * they receive non-pharmacological interventions for their sleep difficulties. * they have been previously diagnosed as having an intellectual disability (iq \< 70). * they have obstructive sleep apnoea, according to the three items in the cshq.

Keywords: behavioural interventions sleep difficulties children attention deficit hyperactivity disorder randomised controlled trial saudi arabia behavioural insomnia
femtosecond laser-assisted corneal debridement for herpes simplex keratitis

Conditions: Herpes Simplex Keratitis

Summary: the purpose of the study is to learn if adding femtosecond laser-assisted corneal debridement to a standard therapy of oral ganciclovir can help shorten the healing time of herpes simplex epithelial keratitis (hsk).


Eligibility criteria:
inclusion criteria: 1. aged between 18 and 80 years old; 2. epithelial ulceration in a dendritic or geographic pattern, characteristic of infection with herpes simplex virus, and within 7 days of onset; 3. ulcer's stromal involvement \< 120 micron, as indicated by anterior segment optical coherence tomography; 4. informed consent signed by patient or legal guardian. having the ability to comply with study assessments for the full duration of the study. exclusion criteria: 1. clinical signs of a cause other than herpes simplex virus for the epithelial keratitis; 2. antivirus or corticosteroid treatment within 6 months; 3. active stromal keratitis or iritis; 4. history of allergy or adverse reaction to ganciclovir; 5. high myopia with a spherical equivalent of -15.0 d or less; 6. corneal or ocular surface infection within 30 days prior to study entry; 7. ocular surface malignancy; 8. uncontrolled diabetes with most recent hemoglobin a1c greater than 8.5%; 9. renal failure with creatinine clearance\< 25ml/min; 10. alanine aminotransferase \> 40iu/l, or aspartate aminotransferase \> 40iu/l; 11. platelet levels \ 450,000 per microliter; 12. hemoglobin \< 12.0 g/dl (male) or \< 11.0 g/dl (female); 13. prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; an international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 14. pregnancy (positive test) or lactation; 15. participation in another simultaneous medical investigation or clinical trial; 16. severe cicatricial eye disease; conjunctival scarring with fornix shortening; 17. severe dry eye disease as determined by schirmer's test \< 2mm at least in one eye; 18. any medical or social condition that in the judgement of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 19. active immunological diseases; 20. history of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
flavor test results in general population

Conditions: Weight, Body; Smoking; Age Problem

Summary: dietary choices are influenced by several factors, including physiological, social or genetic factors. among these, flavor is the most important determinant modulating the preferences versus specific foods. flavor perception is the result from the sensory integration of taste and odor properties of food. aim of the present study was to assess flavor abilities in a large population using a validated perceptive test.

this protocol investigates flavor perception using the flavor test, a specific test to assess the retro-nasal olfactory function. a decrease in taste and smell abilities can result in loss of appetite, inadequate dietary intake and malnutrition. several diseases and conditions have been associated with taste disorders and a decline in gustatory function is very common in the elderly. the flavor test was previously developed, validated and patented by our group. it consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for italian people. each tastant, originally stored in a 30 ml amber bottle, is diluted in distilled water and stored at 4 °c, then it is kept at room temperature for 20 min before administration. an aliquot of approximately 0,5 ml of each tastant is administered in the oral cavity using a 3ml transfer pipet and left for approximately 5 seconds; the mouth is then rinsed twice with distilled water before the administration of the following tastant. at each administration, participants are invited to identify the aromatic by making a choice from 5 proposed items. a total of 21 aromatics (including one blank) are administered sequentially. the flavor score (fs) is calculated as the sum of correctly identified aromatics and ranged from 0 to 21.

Eligibility criteria:
inclusion criteria: age ≥ 18 years exclusion criteria: allergies, drug usage

Keywords: obesity flavor
observational study of the clinico-biological evolution and standard of care offered to patients with ebola virus disease

Conditions: Ebola Virus Disease

Summary: this study highlighted the possibility, even in epidemic settings, of providing advanced supportive care for patients with vmes. indeed, while the prospect of offering any invasive medical care was widely discussed in 2014 in west africa with the aim of limiting the exposure of caregivers, the epidemic of 2018-2019 has on the contrary seen the development of a number of medical care strategies, in parallel with the deployment of specific treatments. this study aims to describe a cohort of patients receiving this upgraded supportive care during the tenth epidemic in the drc.


Eligibility criteria:
inclusion criteria: * laboratory confirmed ebola virus disease exclusion criteria: -
sleep as a mechanism of change in alcohol use

Conditions: Insomnia; Alcohol; Harmful Use

Summary: this project aims to evaluate improvement of insomnia as a mechanism of improvement in alcohol use outcomes.

heavy alcohol use is prevalent in the united states and results in significant physical and psychological burden. one in 10 adults in the united states reports binge drinking on a weekly basis, and few are willing to seek mental health treatment. thus, additional strategies are needed to engage and treat individuals at risk for alcohol-related harm. half of those who screen positive for hazardous drinking report clinically significant symptoms of insomnia. insomnia tends to be less stigmatized than other mental health disorders, and it is one condition for which the field has highly efficacious treatment. thus, one potential strategy to engage individuals in mental health treatment and reduce the burden of alcohol use in the united states is to target insomnia. this project aims (1) to examine change in insomnia as a mediator of insomnia treatment effects on alcohol use outcomes and sex as a moderator of those effects and (2) to identify mechanisms linking change in insomnia to alcohol use outcomes. adults who drink alcohol and have insomnia will be randomly assigned to cognitive behavioral therapy for insomnia (cbt-i, n=112) or waitlist control (wlc, n=112). outcomes will be assessed weekly during treatment, at the end of the active intervention period (post-treatment), and at 1-, 3-, and 6-month follow-ups.

Eligibility criteria:
inclusion criteria: * report heavy drinking in a typical week in the past month * meet dsm-5 criteria for alcohol use disorder * meet dsm-5 and research diagnostic criteria for insomnia disorder exclusion criteria: * ≥50 years * unable to provide informed consent * report contraindications for cbt-i (mania or seizure disorder) * moderate to severe sleep apnea that is untreated * have symptoms requiring immediate clinical attention (e.g., psychosis, suicide plan) * are already receiving behavioral treatment for insomnia or alcohol use

Keywords: alcohol drinking sleep insomnia
searching for the perfect oil to protect the perineum: a randomized-controlled, double-blind trial

Conditions: Second Stage of Labor

Summary: in this study we intend to randomly assign each parturient one of two commonly used oils to be applied during the second stage of labor, one of them containing vitamin e. we will verify if perineal massage increases the chances of delivering with an intact perineum comparing the two oils. as secondary objectives, we will evaluate the effects of perineal massage on specific tear location, the severity of perineal tears and the amount of suture material required for repair.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * term pregnancy exclusion criteria: * non-vertex pregnancies * multiple pregnancies * placenta previa * placental abruption * intra-uterine infection * non progressive labor first stage * former operations or surgical procedures in the vagina * perineal massage during the weeks before labor
active induction of labor in pregnancies complicated with oligohydramnios at term

Conditions: Oligohydramnios

Summary: the purpose of this study is to evaluate the risk of cesarean delivery in pregnancies complicated with isolated oligohydramnios managed by induction of labor. this prospective case-control study was conducted in hamıdıye sisli etfal teaching and research hospital between january 2013 and june 2014. 159 women with isolated oligohydramnios and 165 women with postdate pregnancies who met the inclusion criteria underwent induction of labor with dinoprostone or oxytocin. the rate and the indications of c/s deliveries were compared between two groups.

the study was designed as a prospective study. the rates of cesarean section and maternal/fetal outcomes had been compared between pregnancies complicated with isolated oligohydramnios at term and postdate pregnancies. all patients with isolated oligohydramnios were term (37-40 weeks' gestation according to accurate last menstrual period and first trimester sonographic examination). oligohydramnios was defined as an amniotic fluid index \< 5 cm. the control group consisted of prolonged pregnancies in the absence of spontaneous labor and oligohydramnios. prolonged pregnancy is diagnosed if 41 gestational weeks are completed according to accurate date of last menstrual period and first trimester ultrasound. all patients who accepted to join the study gave informed consent. all patients had a complete physical and obstetrical examination. vital signs were recorded at regular intervals. the primary outcome measure was defined as cesarean section rates in pregnancies complicated with isolated oligohydramnios managed by induction of labor.

Eligibility criteria:
inclusion criteria: * term isolated oligohydramnios * postdate pregnancies * vertex presentation * singleton pregnancies * primigravid and multigravid women exclusion criteria: * women with presence of any chronic disease * maternal condition complicating the pregnancy

Keywords: induction cesarean delivery
surgeon-guided serratus block in breast reduction surgery

Conditions: Postoperative Pain Control; Breast Reduction

Summary: surgeon guided serratus block, which can be performed by the surgeon in participants undergoing breast reduction surgery, may reduce the sensation of pain from the surgical field in the postoperative period. thus, participants experience less pain in the postoperative period, consume less analgesics, and there is a decrease in related complications. the aim of this study was to evaluate the effects of the intraoperative surgeon guided serratus block applied on the analgesic consumption of the participants in the first 24 hours after surgery in participants undergoing breast reduction surgery.


Eligibility criteria:
inclusion criteria: * patient's willingness to be included in the study * 18-65 years * woman * operated with inferior pedicled breast reduction technique * the distance from the sternal notch to the nipple complex is between 25-40cm * asa i-ii * breast usg result birads 1-2 * patients who have not previously received rt to the breast and have no history of malignancy exclusion criteria: * patient's request/refusal not to be included in the study * previous history of malignancy * rt story, * asa 3-4-5-patient group * severe organ failure * alcohol, drug addiction * bupivacaine allergy * diagnosis of psychiatric illness and psychiatric drug use * surgery lasting longer than 3 hours * bleeding diathesis

Keywords: breast reduction postoperative pain control
amevive wisdom acquired from real-time evidence (a.w.a.r.e™) program

Conditions: Plaque Psoriasis

Summary: purpose: to develop a real time national clinical database to support and share best practices, 1. to generate hypotheses for future clinical research 2. to understand how amevive is used in routine clinical practice/real world setting. each patient visit will include the following observational endpoints: 1. amevive dosing 2. number of courses 3. concomitant treatment 4. response to treatment (patient and physician global assessments) 5. status of other psoriasis-related medical conditions 6. time to re-treatment.


Eligibility criteria:
inclusion criteria: * amevive is clinically indicated for the patient exclusion criteria: * amevive is contraindicated for the patient

Keywords: psoriasis plaque psoriasis amevive® alefacept
multinational point prevalence study on the management of diabesity in hospitals

Conditions: Diabetes Mellitus; Obesity

Summary: diabetes related to obesity ("diabesity") is becoming increasingly prevalent. hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays. however, the pharmacological treatment of diabesity has made significant progress in recent years. the objective of this study is to assess the management of diabesity in the international hospital setting. aims include: 1. to determine the prevalence of causes and duration of hospitalization 2. to investigate the treatments used 3. to determine individual metabolic control achived this is a cross-sectional multi-centre study in which researchers will conduct a one-day point prevalence assessment in internal medicine wards.


Eligibility criteria:
inclusion criteria: * hospitalized at the time of the survey for any cause * diabetes diagnosis (known / documented in medical history or newly diagnosed using ada diagnostic criteria) * age ≥ 18 years * written informed consent exclusion criteria: * patients in wards and units other than internal medicine wards (such as outpatient areas, emergency departments, skilled nursing and intensive care units, etc.) * paediatric patients (age \< 18 years) * patients without a diabetes diagnosis